Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,908 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Takaku T, Nakazato T, Tokuhira M, Fujita H, Ando M, Hatta Y, Kawaguchi T. Iriyama N, et al. Among authors: ishikawa m. Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03758-4. Online ahead of print. Int J Hematol. 2024. PMID: 38587692
Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.
Iriyama N, Tokuhira M, Takaku T, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Hatta Y, Kizaki M, Komatsu N, Asou N, Kawaguchi T. Iriyama N, et al. Among authors: ishikawa m. Leuk Res. 2017 Mar;54:55-58. doi: 10.1016/j.leukres.2017.01.003. Epub 2017 Jan 5. Leuk Res. 2017. PMID: 28109974
Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. Sato E, et al. Among authors: ishikawa m. Leuk Lymphoma. 2018 May;59(5):1105-1112. doi: 10.1080/10428194.2017.1365858. Epub 2017 Aug 25. Leuk Lymphoma. 2018. PMID: 28838287
Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto KJ, Fujita H, Fujioka I, Kimura Y, Aisa Y, Iwanaga E, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T. Nakazato T, et al. Among authors: ishikawa m. Med Oncol. 2018 May 30;35(7):99. doi: 10.1007/s12032-018-1159-7. Med Oncol. 2018. PMID: 29846829
Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.
Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T. Fujioka I, et al. Among authors: ishikawa m. Ann Hematol. 2018 Nov;97(11):2081-2088. doi: 10.1007/s00277-018-3412-8. Epub 2018 Jun 26. Ann Hematol. 2018. PMID: 29946911 Clinical Trial.
Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.
Ishikawa M, Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto KJ, Nakazato T, Fujita H, Kimura Y, Fujioka I, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T. Ishikawa M, et al. Oncol Rep. 2019 Dec;42(6):2836-2843. doi: 10.3892/or.2019.7339. Epub 2019 Sep 27. Oncol Rep. 2019. PMID: 31578586
Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Nishiyama-Fujita Y, Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto K, Fujita H, Fujioka I, Tsuchiya S, Kimura Y, Iwanaga E, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T. Nishiyama-Fujita Y, et al. Among authors: ishikawa m. Ann Med. 2022 Dec;54(1):1244-1254. doi: 10.1080/07853890.2022.2069280. Ann Med. 2022. PMID: 35486442 Free PMC article.
Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.
Tsuchiya S, Takaku T, Watanabe N, Iriyama N, Kimura Y, Iwanaga E, Sugimoto KJ, Mitsumori T, Ishikawa M, Nakazato T, Fujita H, Sato E, Hatta Y, Asou N, Kizaki M, Tokuhira M, Ando M, Kawaguchi T. Tsuchiya S, et al. Among authors: ishikawa m. Intern Med. 2023 Nov 15;62(22):3299-3303. doi: 10.2169/internalmedicine.1611-23. Epub 2023 Mar 31. Intern Med. 2023. PMID: 37005261 Free PMC article.
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects.
Tokuhira M, Kimura Y, Tabayashi T, Watanabe N, Tsuchiya S, Takaku T, Iriyama N, Sato E, Nakazato T, Mitsumori T, Ishikawa M, Fujita H, Kizaki M, Ando M, Hatta Y, Iwanaga E, Kawaguchi T. Tokuhira M, et al. Among authors: ishikawa m. Int J Hematol. 2023 Aug;118(2):210-220. doi: 10.1007/s12185-023-03606-x. Epub 2023 May 2. Int J Hematol. 2023. PMID: 37129800
3,908 results